Attention for sex in COVID-19 trials: a review of regulatory dossiers

被引:5
|
作者
de Vries, Sieta T. [1 ,2 ]
Starokozhko, Viktoriia [1 ,2 ]
Schellens, Ingrid M. M. [2 ]
Wijnans, Leonoor [2 ]
Enzmann, Harald [3 ,4 ]
Cavaleri, Marco [5 ]
Mol, Peter G. M. [1 ,2 ,6 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
[2] Dutch Med Evaluat Board, Utrecht, Netherlands
[3] European Med Agcy EMA, Comm Med Prod Human Use, Amsterdam, Netherlands
[4] Bundesinst Arzneimittel & Medizinprod, Bonn, Germany
[5] European Med Agcy EMA, Amsterdam, Netherlands
[6] European Med Agcy EMA, Sci Advice Working Party, Amsterdam, Netherlands
来源
BMJ GLOBAL HEALTH | 2022年 / 7卷 / 03期
关键词
COVID-19; vaccines; treatment; review; public health; GENDER;
D O I
10.1136/bmjgh-2021-008173
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
An under-representation of women and a lack of sex-specific analyses in COVID-19 trials has been suggested. However, the higher number of men than women who are severely affected by COVID-19 and the restricted information in scientific publications may have biased these suggestions. Therefore, we evaluated sex proportionality and sex-specific efficacy and safety data in trials of COVID-19 treatments and vaccines using both publicly available regulatory documents and confidential documents used by regulators in their review of medicinal products. Included were two treatments (ie, remdesivir and dexamethasone) and four vaccines (ie, BNT162b2 mRNA (BioNTech/Pfizer), mRNA-1273 (Moderna), ChAdOx1-S (AstraZeneca) and Ad26.COV2-S (Janssen)) that received marketing authorisation by the European Commission at the time of the study conduct. An under-representation of women was shown in three of the nine data sets for one treatment (ie, remdesivir), but the proportion of women included was representative in each of the data sets for the other five products. This indicates that there is no structural under-representation of women in the COVID-19 trials. Currently, sex-specific efficacy data are available for five of the six assessed products and sex-specific safety data are available for half of the products only. It is important that this information will also be made available for the other products. There are only small differences in efficacy and safety between men and women which are likely to be of limited clinical relevance. Sex-specific efficacy information can generally be found in the publicly available regulatory documents other than the Summary of Product Characteristics, for which more awareness might be required.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The "sex gap" in COVID-19 trials: a scoping review
    Schiffer, Veronique M. M. M.
    Janssen, Emma B. N. J.
    van Bussel, Bas C. T.
    Jorissen, Laura L. M.
    Tas, Jeanette
    Sels, Jan-Willem E. M.
    Bergmans, Dennis C. J. J.
    Dinh, Trang H. T.
    van Kuijk, Sander M. J.
    Hana, Anisa
    Mehagnoul-Schipper, Jannet
    Scheeren, Clarissa I. E.
    Mesotten, Dieter
    Stessel, Bjorn
    Marx, Gernot
    van't Hof, Arnoud W. J.
    Spaanderman, Marc E. A.
    van Mook, Walther N. K. A.
    van der Horst, Iwan C. C.
    Ghossein-Doha, Chahinda
    [J]. ECLINICALMEDICINE, 2020, 29-30
  • [2] A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
    Heidari, Shirin
    Palmer-Ross, Alice
    Goodman, Tracey
    [J]. VACCINES, 2021, 9 (11)
  • [3] OUTCOMES EXAMINED IN CLINICAL TRIALS OF MEDICINES FOR COVID-19: A REVIEW OF REGULATORY AGENCIES' WEBSITES
    Rojas, P.
    Epp, C.
    Gozzo, L.
    Geba, D.
    Epstein, M.
    Michel, S.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S515 - S516
  • [4] Clinical trials for COVID-19 should include sex as a variable
    Bischof, Evelyne
    Wolfe, Jeannette
    Klein, Sabra L.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2020, 130 (07): : 3350 - 3352
  • [5] COVID-19 vaccine trials and sex-disaggregated data
    Hussain, Musaddique
    Fatima, Mehwish
    Muhammad Iqbal, Shahid
    Asif, Muhammad
    Saadullah, Malik
    Kashif-Ur-Rehman
    Mukhtar, Imran
    Ahmad Khan, Imran
    Parveen, Sajida
    Fayyaz, Tehreem
    Shabbir, Najia
    Kanwal, Aisha
    Shaukat, Saira
    Fatima, Mobeen
    Ikram, Nadia
    Majeed, Abdul
    Parveen, Farzana
    Tariq, Muhammad
    Barkat, Muhammad Qasim
    Zeng, Ling-Hui
    Wu, Ximei
    [J]. EXPERT REVIEW OF VACCINES, 2022, 21 (03) : 285 - 288
  • [6] Sex-disaggregated data in COVID-19 vaccine trials
    Vijayasingham, Lavanya
    Bischof, Evelyne
    Wolfe, Jeannette
    [J]. LANCET, 2021, 397 (10278): : 966 - 967
  • [7] Review of registered clinical trials for the treatment of COVID-19
    Babaei, Fatemeh
    Mirzababaei, Mohammadreza
    Nassiri-Asl, Marjan
    Hosseinzadeh, Hossein
    [J]. DRUG DEVELOPMENT RESEARCH, 2021, 82 (04) : 474 - 493
  • [8] COVID-19 AND SEX
    Seymour, Zachary
    Moran, Michael
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E206 - E206
  • [9] COVID-19, sex, and gender in China: a scoping review
    Feng, Huiyun
    Gan, Connie Cai Ru
    Leiva, Diego
    Zhang, Bao Ling
    Davies, Sara E.
    [J]. GLOBALIZATION AND HEALTH, 2022, 18 (01)
  • [10] COVID-19, sex, and gender in China: a scoping review
    Huiyun Feng
    Connie Cai Ru Gan
    Diego Leiva
    Bao Ling Zhang
    Sara E. Davies
    [J]. Globalization and Health, 18